miRNA替代能否成为肾上腺皮质癌的新疗法

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2016-01-18 DOI:10.2217/IJE.15.28

A. Glover, Nunki Hassan, L. J. S. Joo, Grace T Y Kwok, Jing Zhao, S. Sidhu

{"title":"miRNA替代能否成为肾上腺皮质癌的新疗法","authors":"A. Glover, Nunki Hassan, L. J. S. Joo, Grace T Y Kwok, Jing Zhao, S. Sidhu","doi":"10.2217/IJE.15.28","DOIUrl":null,"url":null,"abstract":"Adrenocortical carcinoma (ACC) has poor outcomes and there is a need for novel effective treatments for metastatic disease and adjuvant therapy. miRNAs are small endogenous noncoding RNAs that control gene expression. miRNAs are dysregulated in all cancers and manipulation of miRNA levels is under investigation as a novel therapy in other cancers with poor outcomes such as mesothelioma. In this review, the rationale for miRNA therapy will be presented along with the current understanding of the role of miRNA dysregulation and miRNA regulation of ACC. Potential therapeutic approaches of miRNA therapy using established delivery systems such as liposomes and targeted nanocells will be presented, along with the future challenges of establishing miRNA therapy in clinical trials for ACC.","PeriodicalId":42691,"journal":{"name":"International Journal of Endocrine Oncology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2016-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJE.15.28","citationCount":"0","resultStr":"{\"title\":\"Could miRNA replacement be a novel therapy for adrenocortical carcinoma\",\"authors\":\"A. Glover, Nunki Hassan, L. J. S. Joo, Grace T Y Kwok, Jing Zhao, S. Sidhu\",\"doi\":\"10.2217/IJE.15.28\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Adrenocortical carcinoma (ACC) has poor outcomes and there is a need for novel effective treatments for metastatic disease and adjuvant therapy. miRNAs are small endogenous noncoding RNAs that control gene expression. miRNAs are dysregulated in all cancers and manipulation of miRNA levels is under investigation as a novel therapy in other cancers with poor outcomes such as mesothelioma. In this review, the rationale for miRNA therapy will be presented along with the current understanding of the role of miRNA dysregulation and miRNA regulation of ACC. Potential therapeutic approaches of miRNA therapy using established delivery systems such as liposomes and targeted nanocells will be presented, along with the future challenges of establishing miRNA therapy in clinical trials for ACC.\",\"PeriodicalId\":42691,\"journal\":{\"name\":\"International Journal of Endocrine Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2016-01-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/IJE.15.28\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Endocrine Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/IJE.15.28\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Endocrine Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/IJE.15.28","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

肾上腺皮质癌(ACC)预后差，需要新的有效治疗转移性疾病和辅助治疗。mirna是控制基因表达的小内源性非编码rna。miRNA在所有癌症中都是失调的，操纵miRNA水平作为一种治疗间皮瘤等预后不良癌症的新疗法正在研究中。在这篇综述中，将介绍miRNA治疗的基本原理以及目前对miRNA失调和miRNA调控ACC的作用的理解。将介绍利用脂质体和靶向纳米细胞等已建立的递送系统进行miRNA治疗的潜在治疗方法，以及在ACC临床试验中建立miRNA治疗的未来挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Could miRNA replacement be a novel therapy for adrenocortical carcinoma

Adrenocortical carcinoma (ACC) has poor outcomes and there is a need for novel effective treatments for metastatic disease and adjuvant therapy. miRNAs are small endogenous noncoding RNAs that control gene expression. miRNAs are dysregulated in all cancers and manipulation of miRNA levels is under investigation as a novel therapy in other cancers with poor outcomes such as mesothelioma. In this review, the rationale for miRNA therapy will be presented along with the current understanding of the role of miRNA dysregulation and miRNA regulation of ACC. Potential therapeutic approaches of miRNA therapy using established delivery systems such as liposomes and targeted nanocells will be presented, along with the future challenges of establishing miRNA therapy in clinical trials for ACC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.